• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Eli Lilly (NY:LLY)

    1,184.78 UNCHANGED
    Streaming Delayed Price Updated: 7:00 PM EDT, Sep 28, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Eli Lilly

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    99 100 Next >
    News headline image
    Want a $1 Million Investment Portfolio? History Says This Strategy Could Get You There. ↗
    Consistency is one of the biggest factors in making it happen. 
    Via The Motley Fool
    Topics ETFs Economy
    News headline image
    2026 Nanocap Stocks to Watch: IGC, KNRX, GYGY, ARAY Lead Watchlist Now See More Inside!
    Via AB Newswire
    Topics Artificial Intelligence
    News headline image
    VivoSim Labs Inc. (NASDAQ: VIVS) Targets the Multibillion-Dollar Cost of Failed Drugs
    Via AB Newswire
    News headline image
    2 of the Best ETFs to Buy When Inflation Is Running Hot ↗
    Higher inflation rates have caused investors to rethink their portfolios. 
    Via The Motley Fool
    Topics ETFs Economy
    Eli Lilly (NYSE:LLY) Offers a Breakout Setup Backed by High Growth Momentum ↗
    Via Chartmill
    News headline image
    Could This Mid-Cap GLP-1 Stock Be a Better Buy Than Eli Lilly? ↗
    Shares of Viking Therapeutics took off recently after the company released some promising data about its GLP-1 drug. 
    Via The Motley Fool
    News headline image
    Eli Lilly Just Announced Game-Changing News ↗
    Something new is happening in the weight loss drug market. 
    Via The Motley Fool
    News headline image
    Viking Therapeutics (VKTX) Delivers Great VK2735 Results: Here's a Word of Caution ↗
    The company recently delivered some exciting trial data, but it also needs to deliver in the second part of the trial. 
    Via The Motley Fool
    News headline image
    Here's Where Wall Street Analysts See Eli Lilly's Share Price Going ↗
    Eli Lilly's share price climb has decelerated in 2026. 
    Via The Motley Fool
    News headline image
    Lilly Cut an Obesity Drug -- but the Move Shows How High Its Bar Has Become ↗
    Eli Lilly is the leader in the GLP-1 space, but not every new drug the company is working on will be a winner. 
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Guess Which Group of Stocks Is Back at an All-Time High? ↗
    The "Magnificent Seven" ETF finally topped the record high it set in May. 
    Via The Motley Fool
    Topics Artificial Intelligence ETFs Electric Vehicles
    News headline image
    MarketBeat Week in Review – 09/21 - 09/25 ↗
    A weekly roundup of MarketBeat analysis on volatile markets, oil, bond rates, AI stocks, dividend picks, and earnings outlooks, covering companies from NVIDIA to Tesla and Qualcomm. 
    Via MarketBeat
    Topics Artificial Intelligence Bonds Economy
    News headline image
    Could This Be Novo Nordisk’s Next Billion-Dollar Weight-Loss Product? ↗
    The drugmaker badly needs more clinical wins. 
    Via The Motley Fool
    News headline image
    Viking Therapeutics Soared After Its Latest GLP-1 Data. Is It Too Late to Buy? ↗
    The biotech player could eventually rival big pharma companies. 
    Via The Motley Fool
    News headline image
    2 Healthcare Stocks with Impressive Fundamentals and 1 Facing Challenges
    Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only reali... 
    Via StockStory
    News headline image
    AbbVie vs. Eli Lilly: Which Star Pharma Stock Is a Better Buy in 2026? ↗
    AbbVie leans on legacy income and portfolio transition, while Eli Lilly rides explosive growth in weight-loss drugs, but at vastly different valuations. 
    Via The Motley Fool
    News headline image
    Eli Lilly (LLY) Stock Is Up, What You Need To Know
    What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.1% in the afternoon session after The U.S. Food and Drug Administration ... 
    Via StockStory
    Explore the top gainers and losers within the S&P500 index in today's session. ↗
    Via Chartmill
    News headline image
    XLV vs IBB: How Healthcare Diversification Compares to Biotech Concentration ↗
    XLV offers exposure to the broader healthcare sector, while IBB targets biotech innovators. Here's how the two stack up on risk, returns, and diversification. 
    Via The Motley Fool
    Topics ETFs
    News headline image
    Fidelity Healthcare ETF (FHLC) vs. VanEck Biotech ETF (BBH): Which Fund Is the Better Buy? ↗
    VanEck's concentrated 25-stock biotech portfolio surged 40.5% in one year, but Fidelity's diversified 365-holding fund delivered superior risk-adjusted returns with half the volatility. 
    Via The Motley Fool
    Topics ETFs
    News headline image
    Stanley Druckenmiller, Ken Griffin, and Cathie Wood Have at Least 1 Thing in Common: They All Own This Stock ↗
    This company is a leader in a high-growth field. 
    Via The Motley Fool
    News headline image
    XLV vs. PJP: How Broad Healthcare Diversification Stacks Up to Pharma Stocks ↗
    XLV's broader diversification and lower fees appeal to cost-conscious investors, while PJP's concentrated pharma bet has outperformed over the past year. 
    Via The Motley Fool
    Topics ETFs
    News headline image
    Could Retatrutide Be Worth $10 Billion to Eli Lilly? ↗
    The company continues to dominate the weight loss market. 
    Via The Motley Fool
    Topics Law Enforcement
    News headline image
    Viking's Obesity Edge May Be Staying Power, Not Weight Loss ↗
    Viking Therapeutics shares jumped 36% after VK2735 maintenance data showed patients kept most weight loss on less frequent dosing, though Phase 3 results and commercial funding remain unresolved. 
    Via MarketBeat
    News headline image
    Eli Lilly Keeps Pulling Ahead—Can Novo Nordisk Catch Up? ↗
    Eli Lilly leads Novo Nordisk in GLP-1 market share and analyst sentiment, while Novo pins hopes on its CagriSema catalyst and pipeline to offset patent-cliff pressure and lawsuits. 
    Via MarketBeat
    Topics Intellectual Property Lawsuit
    News headline image
    Why Viking Therapeutics Stock Skyrocketed on Tuesday ↗
    The biotech's obesity drug candidate could make it easier for people who have recently lost weight to keep it off. 
    Via The Motley Fool
    News headline image
    Better Healthcare ETF: Invesco's Biotech-Focused IBBQ vs. iShares' Broad IYH ↗
    IBBQ offers concentrated biotech exposure with lower costs and stronger recent returns, while IYH provides broader sector diversification and higher dividend income. 
    Via The Motley Fool
    Topics ETFs
    News headline image
    Novo Nordisk Has a Fresh New Name -- but It Still Faces the Same Old Problems ↗
    Novo Nordisk is dealing with headwinds, but was its name really one of the big problems? 
    Via The Motley Fool
    News headline image
    VHT vs. XBI: Is Diversified Healthcare Exposure or Biotech Stocks the Smarter Choice for Investors? ↗
    VHT offers broad sector exposure with lower volatility, while XBI concentrates on biotech with higher risk and reward. Here's how to decide between the two. 
    Via The Motley Fool
    Topics ETFs
    News headline image
    Oura’s $15.6 Billion IPO Is Betting Investors See More Than a Smart Ring ↗
    Oura's IPO targets a $12.8B-$14.1B valuation, pricing shares at $40-$44 ahead of its Nasdaq debut, backed by Eli Lilly interest and strong subscription revenue growth. 
    Via MarketBeat
    Topics Initial Public Offering
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    99 100 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.